Moderna (MRNA) Stock
$236.50
+4.51% Close Oct 15
MRNA stock sits 2.39% below its 52-week high of $242.29 after rising 961.49% from its 52-week low.
Open interactive chartMRNA stock price today
MRNA stock closed at $236.50 on Oct 15, 2026, up 4.51% from the prior close of $226.30. The day's range ran from $217.02 to $242.29. Volume reached 17.3 million shares against a 50-day average of 22.7 million. The stock returned 62.41% over one month and 800.95% over one year.
- Last close
- $236.50
- Day range
- $217.02 to $242.29
- 52-week range
- $22.28 to $242.29
- From 52-week high
- −2.4%
- Average volume (50 days)
- 22.7M
- 1 week
- +20.1%
- 1 month
- +62.4%
- 3 months
- +282.6%
- Year to date
- +702.0%
- 1 year
- +801.0%
- 3 years
- +126.5%
- 5 years
- −23.6%
Is MRNA stock in an uptrend?
Yes, MRNA stock is in an uptrend: it meets the Minervini Trend Template criteria and both Daily Pivot Breakout momentum filters are active. Price is above its 200-day moving average.
Yes, MRNA stock is in an uptrend: it meets the Minervini Trend Template criteria and both Daily Pivot Breakout momentum filters are active. Price is above its 200-day moving average. Both filters are active: the 100-day ROC is 404.48% against a minimum of 40%, and the 100-day EMA slope is 167.98% against a minimum of 25%. The Trend Template matched on Oct 15, 2026. The 20-day average sits at $197.98, the 50-day at $151.65, the 150-day at $87.07 and the 200-day at $76.46, stacked in uptrend order.
- Daily Pivot momentum filters
- 2 of 2 active
- 100-day ROC
- +404.5% filter at 40%: active
- 100-day EMA slope
- +168.0% filter at 25%: active
- Trend state
- Uptrend
- Minervini Trend Template
- Met on Oct 15
- 50-day average
- Above
- 150-day average
- Above
- 200-day average
- Above
- 200-day slope (1 month)
- +29.72%
- ATR (14) % of price
- 7.29%
Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.
MRNA support and resistance levels
MRNA stock trades 9.28% below its 9-day EMA at $214.55, the nearest level in the data. The 21-day EMA sits at $195.74, 17.23% under the close. The Daily Pivot high is $156.41 and the latest Daily Pivot low is $130.38. The 50-day SMA at $151.65 sits 35.88% below the close.
| Level | Price | From close |
|---|---|---|
| 9-day EMA | $214.55 | −9.3% |
| 21-day EMA | $195.74 | −17.2% |
| Daily Pivot resistance (pivot high) | $156.41 | −33.9% |
| 50-day SMA | $151.65 | −35.9% |
| Latest Daily Pivot low | $130.38 | −44.9% |
| 30-week SMA | $91.46 | −61.3% |
| 150-day SMA | $87.07 | −63.2% |
| 200-day SMA | $76.46 | −67.7% |
Levels above the close act as resistance, levels below as support. Last close $236.50.
MRNA breakout and scanner signals
MRNA stock has several bullish scanner readings. The Minervini Trend Template scanner last fired on Oct 8, 2026, and a newer signal appeared in the recent sessions, which members can see in the journal. The Daily Pivot Breakout last fired on Aug 10, 2026. The Episodic Pivot and Ichimoku TK cross both last fired on Aug 19, 2026, and the 9/21 EMA cross on Aug 13, 2026.
| Scanner | Last signal (free view, 5 sessions late) | Past year |
|---|---|---|
| Daily Pivot Breakout | Aug 10, 2026 | 5 |
| Minervini Trend Template | Oct 8, 2026New signal in the last 5 sessions. See it in the journal. | 37 |
| Episodic Pivot | Aug 19, 2026 | 1 |
| Ichimoku TK cross | Aug 19, 2026 | 2 |
| 9/21 EMA cross | Aug 13, 2026 | 2 |
MRNA seasonality by month
MRNA stock has its strongest average month in November, at 20.6% with a 71% up rate across seven years. August averages 11.66% but has a median of -8.17%, a wide gap between the two. October averages -3.22% with a 43% up rate.
- Jan+11.2%63% up
- Feb+1.6%38% up
- Mar+1.9%50% up
- Apr+9.7%63% up
- May+5.8%63% up
- Jun+3.9%50% up
- Jul+6.6%63% up
- Aug+11.7%38% up
- Sep+3.0%63% up
- Oct−3.2%43% up
- Nov+20.6%71% up
- Dec−3.3%43% up
Average monthly return over 8+ years of stored daily closes, and the share of years each month closed higher.
MRNA earnings history
MRNA stock's most recent reported quarter, dated Jul 31, 2026, posted an EPS of -1.97 against an estimate of -2.06, a surprise of -4.37%. The May 22, 2026 report came in at 1.78 against an estimate of 1.34, a surprise of 32.84%. The May 1, 2026 report showed -3.40 against -3.88, a surprise of -12.37%. Trailing EPS stands at -8.35.
| Reported | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 31, 2026 | $-2.06 | $-1.97 | −4.4% |
| May 22, 2026 | $1.34 | $1.78 | +32.8% |
| May 1, 2026 | $-3.88 | $-3.40 | −12.4% |
| Mar 17, 2026 | $0.42 | $0.65 | +54.8% |
| Mar 4, 2026 | $0.06 | $0.15 | +150.0% |
MRNA bull and bear case
MRNA stock's bullish list includes both Daily Pivot momentum filters being active, the 50, 150 and 200-day averages stacked in uptrend order, and a close above Daily Pivot resistance. The bearish list is empty in the data. The one listed risk is negative net income over the last year, with trailing net income of about -$3.15 billion.
What looks strong
- Both Daily Pivot momentum filters are active (100-day ROC 404.5%, 100-day EMA slope 168.0%).
- Met the Minervini Trend Template on 2026-10-15.
- The 50, 150 and 200-day averages are stacked in uptrend order.
- Price is above a rising 200-day moving average.
- Price closed above its Daily Pivot resistance level.
- Had a Daily Pivot Breakout on 2026-08-10.
- Had an Episodic Pivot gap on 2026-08-19.
What looks weak
Drawn only from the data on this page. Not a recommendation.
MRNA news and SEC filings, last 30 days
MRNA stock has two recent filings. A Form 4 is dated Oct 7, 2026 with no labels. An 8-K dated Sep 30, 2026 carries the labels executive or director change, Reg FD disclosure and exhibits.
Source: SEC EDGAR.
MRNA insider trading and risks
MRNA stock shows no insider buys or sells in the recent window, with zero net shares and zero dollar value. The largest insider transactions list is empty. Insiders hold 7.3% of shares outstanding.
- Buys, last 90 days
- 0 ($0)
- Sales, last 90 days
- 0 ($0)
- Buys, last 12 months
- 0 ($0)
- Sales, last 12 months
- 0 ($0)
Risk flags from the data
- Net income over the last 12 months is negative.
Insider trades: SEC Form 4 open-market purchases and sales.
MRNA valuation and fundamentals
MRNA stock has a trailing P/E of 24.97 and a market cap of $94.4 billion. The forward P/E is -53.29 and EV/EBITDA is -41.26, reflecting negative earnings. Price-to-sales is 42.38 and price-to-book is 13.96. Operating cash flow is -$1.07 billion while free cash flow is $299.2 million.
- Market cap
- $94.42B
- Enterprise value
- $90.57B
- P/E (trailing)
- 25.0
- P/E (forward)
- -53.3
- PEG
- -3.32
- Price to sales
- 42.38
- Price to book
- 13.96
- EV to EBITDA
- -41.3
- Gross margin
- +35.0%
- Operating margin
- −557.9%
- Profit margin
- −141.4%
- Return on equity
- −39.0%
- Revenue (TTM)
- $2.23B
- Revenue growth (quarter, y/y)
- +2.1%
- Cash
- $5.14B
- Debt
- $1.29B
- Beta
- 1.10
MRNA dividends and splits
MRNA stock pays no dividend, with a yield of 0% and a payout of 0%. No recent dividend payments are listed. No splits are listed either.
- Dividend yield
- 0.00%
- Payout ratio
- 0.0%
Who owns MRNA?
- Shares outstanding
- 399.0M
- Float
- 372.1M
- Held by insiders
- +7.3%
- Held by institutions
- +80.4%
- Short interest (% of shares)
- +9.4%
- Days to cover
- 2.0
What does Moderna Inc. do?
MRNA stock belongs to the Healthcare sector and the Biotechnology industry. Moderna Inc. is headquartered in Cambridge, MA, and reports 4,700 employees. Its CEO is Mr. Stéphane Bancel M.B.A. The company develops medicines and vaccines based on messenger RNA technology.
- CEO
- Mr. Stéphane Bancel M.B.A.
- Employees
- 4,700
- Headquarters
- Cambridge, MA, United States
- Website
- modernatx.com
MRNA stock FAQ
Is MRNA stock in an uptrend?
Yes, MRNA stock is in an uptrend: it meets the Minervini Trend Template criteria and both Daily Pivot Breakout momentum filters are active. Price is above its 200-day moving average.
What is the MRNA stock price today?
MRNA stock closed at $236.50 on Oct 15, 2026, up 4.51% from the prior close of $226.30. The day's high was $242.29 and the low was $217.02.
What are the MRNA stock support levels?
The nearest level in the data for MRNA stock is the 9-day EMA at $214.55, followed by the 21-day EMA at $195.74. Lower reference levels are the Daily Pivot high at $156.41 and the latest Daily Pivot low at $130.38.
What were the recent MRNA stock earnings results?
MRNA stock's most recent reported quarter, dated Jul 31, 2026, showed an EPS of -1.97 against an estimate of -2.06. The May 22, 2026 report beat its estimate with 1.78 against 1.34.
Is there insider selling in MRNA stock?
MRNA stock shows no insider sells in the recent window, and the insider transaction list is empty. Insiders hold 7.3% of shares outstanding.
Is MRNA stock seasonal?
MRNA stock's strongest average month is November, at 20.6% with a 71% up rate over seven years. October has averaged -3.22% with a 43% up rate.
What is the bull and bear case for MRNA stock?
The bullish case rests on both Daily Pivot momentum filters being active and the 50, 150 and 200-day averages stacked in uptrend order. The bearish list is empty, and the one listed risk is negative net income over the last year.
What recent filings does MRNA stock have?
MRNA stock has a Form 4 dated Oct 7, 2026 with no labels. It also has an 8-K dated Sep 30, 2026 labeled executive or director change, Reg FD disclosure and exhibits.